2023 World Conference on Lung Cancer (Posters)-EP13.07. Understanding Real-Life Response to Lurbinectedin as Second Line Therapy in Patients with Extensive Stage Small-Cell Lung Cancer

EP13.07. Understanding Real-Life Response to Lurbinectedin as Second Line Therapy in Patients with Extensive Stage Small-Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

Lurbinectedin is a recently approved treatment for extensive-stage small cell lung cancer (ES-SCLC) after progression on platinum-based chemotherapy. The approval was based on the results of a phase II trial that showed promising activity and tolerability of the drug. However, the trial did not include certain patient populations, such as those with central nervous system (CNS) involvement or prior use of immune checkpoint inhibitors (ICI).<br /><br />A retrospective chart review was conducted to investigate the real-world efficacy and tolerance of lurbinectedin in a patient population at the University of Michigan Rogel Cancer Center. The analysis included adults with biopsy-proven small cell lung cancer who received lurbinectedin as second-line therapy.<br /><br />The study found that the real-world patient population differed from the trial population in several clinically meaningful ways. Patients in the real-world cohort had a higher incidence of serious adverse events, including a case of tumor lysis syndrome, and a greater percentage required dose delays or reductions due to toxicity.<br /><br />The median progression-free survival (PFS) and overall survival (OS) in the real-world cohort were shorter compared to the trial results. The study also found that patients who had received prior immune checkpoint inhibitors had longer PFS and OS, and a longer platinum therapy-free interval was associated with better outcomes.<br /><br />In conclusion, the real-world efficacy of lurbinectedin may not be as robust as initially reported. The study identified differences in patient characteristics and outcomes, as well as a higher rate of serious adverse events. Further research with a larger patient population is needed to validate these findings.<br /><br />Overall, this study provides valuable insights into the real-life response to lurbinectedin as a second-line therapy for ES-SCLC, highlighting the importance of considering patient characteristics and tolerability in clinical decision-making.

Asset Subtitle

Katherine Curt

Meta Tag

Speaker Katherine Curt

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

Lurbinectedin

ES-SCLC

platinum-based chemotherapy

real-world efficacy

tolerability

immune checkpoint inhibitors

progression-free survival

overall survival

serious adverse events

patient characteristics